Information Provided By:
Fly News Breaks for March 14, 2019
AMAG
Mar 14, 2019 | 06:54 EDT
Cantor Fitzgerald analyst Matthew Lillis lowered his price target for Amag Pharmaceuticals to $14 from $17 saying failure of the post-approval Makena trial is a "clear setback for the company." The trial result reinforces the importance of the next 12-18 months for Amag to demonstrate that existing and pipeline assets can adequately replace lost Makena revenue, Lillis tells investors in a research note. He reiterates a Neutral rating on the shares.
News For AMAG From the Last 2 Days
There are no results for your query AMAG
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.